Start long or short acting BD Long acting preferred unless SOB is only occasional A Inhaled is preferred vs oral A Regular and prn SAMA or SABA use improves FEV1 and sx A SABA SAMA combos more effective than mono tx A LABAs and LAMAs improve dyspnea reduc

By rray, 22 February, 2024
Exclude Patient Type Detail Header
No
Detail Type
Text
Detail Text
LAMA options aclidinium glycopyrrolate revefenacin tiotropium DPI MDI umeclidinium
LABA options arformoterol formoterol olodaterol salmeterol
SAMA ipratropium MDI NEB
SABA options albuterol levalbuterol MDI NEB
Oral theophylline has small bronchodilator effect A and assoc w modest sx benefit B Disadvantages low therapeutic ratio and many toxic effects arrhythmias sz drug interactions others
Patient Type Detail Header (Long)
<b>Start long- or short-acting BD.</b> Long-acting preferred unless SOB is only occasional [A]. <b>Inhaled is preferred vs. oral</b> [A]. Regular and prn SAMA or SABA use improves FEV<sub>1</sub> and sx [A]; SABA+SAMA combos more effective than mono-tx [A]. LABAs and LAMAs improve dyspnea, reduce exac rate [A]. LAMAs reduce exac [A]and hospitalizations [B]more than LABAs; combos more effective than mono-tx [B]. Tailor choice of inhaler to pt’s ability and preference. Minimize number of devices.